Viromed Medical AG (Q11) - Total Liabilities
Based on the latest financial reports, Viromed Medical AG (Q11) has total liabilities worth €69.84 Million EUR (≈ $81.65 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Q11 year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Viromed Medical AG - Total Liabilities Trend (2021–2024)
This chart illustrates how Viromed Medical AG's total liabilities have evolved over time, based on quarterly financial data. See Q11 cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
Viromed Medical AG Competitors by Total Liabilities
The table below lists competitors of Viromed Medical AG ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Shenmao Technology Inc
TW:3305
|
Taiwan | NT$6.84 Billion |
|
Taiyuan Lionhead Cement Co Ltd
SHG:600539
|
China | CN¥104.58 Million |
|
Kneat.com Inc
TO:KSI
|
Canada | CA$56.74 Million |
|
Unipar Carbocloro S.A
SA:UNIP3
|
Brazil | R$5.57 Billion |
|
Tibet Aim Pharm Inc
SHE:002826
|
China | CN¥265.27 Million |
|
Frontera Energy Corp
TO:FEC
|
Canada | CA$1.20 Billion |
|
Albaraka Turk Katilim Bankasi AS
IS:ALBRK
|
Turkey | TL397.50 Billion |
|
Levinstein Eng
TA:LEVI
|
Israel | ILA2.21 Billion |
Liability Composition Analysis (2021–2024)
This chart breaks down Viromed Medical AG's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Q11 market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.56 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.26 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.21 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Viromed Medical AG's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Viromed Medical AG (2021–2024)
The table below shows the annual total liabilities of Viromed Medical AG from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €54.82 Million ≈ $64.09 Million |
+27.60% |
| 2023-12-31 | €42.96 Million ≈ $50.23 Million |
+2199.62% |
| 2022-12-31 | €1.87 Million ≈ $2.18 Million |
-33.59% |
| 2021-12-31 | €2.81 Million ≈ $3.29 Million |
-- |
About Viromed Medical AG
Viromed Medical AG engages in the development and distribution of products in diagnostics, therapeutics, and cold plasma technology. The company was formerly known as Fonterelli SPAC2 AG. Viromed Medical AG was incorporated in 2021 and is based in Pinneberg, Germany.